SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

ETEX Corporation announces appointment of Stephen R. La Neve as President and Chief Executive Officer

CAMBRIDGE, Mass., Jan. 7, 2014 /PRNewswire/ -- ETEX Corporation, an advanced biomaterials company, today announced the appointment of Stephen R. La Neve, MBA, as President and Chief Executive Office.

Steve brings over 30 years of healthcare achievement and leadership to the position. He has held executive management roles in both medical device and diagnostic segments, most recently as the Co-Founder and CEO of SkelRegen, LLC. This was preceded by a number of domestic and international senior executive positions with Medtronic, Becton Dickinson and Premier.

Steve holds a B.S. in Health Planning and Administration from Pennsylvania State University and an MBA from West Chester University.

"We are pleased to introduce Stephen La Neve as the new President and CEO of ETEX Corporation. Steve's track record of commercial success across a range of domestic and international markets will prove invaluable as he drives ETEX forward," states ETEX's Board of Directors.

Stephen La Neve comments: "I am excited to join ETEX at a time when the company is poised for significant growth. We will drive top line revenue by expanding our domestic and international sales presence while pursuing multiple strategic opportunities to transform ETEX into the largest pure-play biologics company in the industry."

About ETEX Corporation
Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.

SOURCE ETEX Corporation

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.